                         SEQUENCE LISTING

<110>  RAPHA LLC
 
<120>  Compositions for Treatment of Cancers

<130>  037847-531001WO

<140>  Herewith
<141>  2021-11-23

<150>  US 63/117,949
<151>  2020-11-24

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  112
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  Isolated polypeptide comprising full-length musarin

<220>
<221>  MISC_FEATURE
<222>  (22)..(22)
<223>  Cysteine residue participating in formation of a disulfide bond

<220>
<221>  MISC_FEATURE
<222>  (111)..(111)
<223>  Cysteine residue participating in formation of a sulfide bond

<400>  1

Met Ser Ser Val Ser Met Ser Ala Leu Tyr Ala Ser Ala Ile Leu Trp 
1               5                   10                  15      


Tyr Ile Asp Gln Gln Cys Leu Asn Val Gly Asp Glu Ala Trp Val Val 
            20                  25                  30          


Leu Ala Gly Arg Arg Ser Pro Asp Leu Gln Gly Glu Thr Thr Ala Tyr 
        35                  40                  45              


Pro Ala Ile Arg Met Gly Asp Leu Arg Gly Leu Ala Glu Leu Asp Val 
    50                  55                  60                  


Asn Ala Ala Asn Asp Val Phe His Arg Phe Leu Gly Arg Ser Gly Glu 
65                  70                  75                  80  


Tyr Tyr Arg Glu Gly Ala Ser Pro Thr Pro Arg Gly Tyr Leu Leu Thr 
                85                  90                  95      


Ile Phe Ala Ala Ile Ala Gly Leu Phe Ala Leu Gly Val Tyr Cys Tyr 
            100                 105                 110         


<210>  2
<211>  91
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  Cytoplasmic domain of musarin

<400>  2

Met Ser Ser Val Ser Met Ser Ala Leu Tyr Ala Ser Ala Ile Leu Trp 
1               5                   10                  15      


Tyr Ile Asp Gln Gln Cys Leu Asn Val Gly Asp Glu Ala Trp Val Val 
            20                  25                  30          


Leu Ala Gly Arg Arg Ser Pro Asp Leu Gln Gly Glu Thr Thr Ala Tyr 
        35                  40                  45              


Pro Ala Ile Arg Met Gly Asp Leu Arg Gly Leu Ala Glu Leu Asp Val 
    50                  55                  60                  


Asn Ala Ala Asn Asp Val Phe His Arg Phe Leu Gly Arg Ser Gly Glu 
65                  70                  75                  80  


Tyr Tyr Arg Glu Gly Ala Ser Pro Thr Pro Arg 
                85                  90      


<210>  3
<211>  19
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  Transmembrane domain of musarin

<400>  3

Gly Tyr Leu Leu Thr Ile Phe Ala Ala Ile Ala Gly Leu Phe Ala Leu 
1               5                   10                  15      


Gly Val Tyr 
            


<210>  4
<211>  20
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  TMhelix domain of musarin

<400>  4

Gly Tyr Leu Leu Thr Ile Phe Ala Ala Ile Ala Gly Leu Phe Ala Leu 
1               5                   10                  15      


Gly Val Tyr Cys 
            20  


<210>  5
<211>  175
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  GGDEF domain of the hypothetical protein

<400>  5

Leu Ser Glu Gln Arg Asp Ile Leu Asp Arg Leu Ala Ala Ile Asp Pro 
1               5                   10                  15      


Leu Thr Gly Leu Ser Asn Arg Arg Gly Leu Asp Ile Ala Leu Ala Lys 
            20                  25                  30          


Asp Ile Glu Asn Ala Gly Asp Gln Ala Trp Val Val Leu Ala Met Leu 
        35                  40                  45              


Asp Ile Asp Ser Phe Lys Pro Tyr Asn Asp Asn Tyr Gly His Pro Ala 
    50                  55                  60                  


Gly Asp Glu Ala Leu Lys Leu Val Ala Lys Ala Leu Asp Tyr Ala Leu 
65                  70                  75                  80  


Asp Gly His Thr Arg Leu Ala Arg Ile Gly Gly Glu Glu Phe Val Ala 
                85                  90                  95      


Val Gln Val Ala Arg Glu Leu Pro Asp Ile Ala Pro Phe Ala Glu Gln 
            100                 105                 110         


Phe Arg Ala Ala Val Glu Arg Leu Ala Leu Pro His Gly Tyr Ser Val 
        115                 120                 125             


Thr Thr Asp Val Val Thr Val Ser Val Gly Ala Ser Ala Gly Val Leu 
    130                 135                 140                 


Asp Glu Asp Gly Ser Leu Lys Ser Leu Phe Thr Val Ala Asp Arg Ala 
145                 150                 155                 160 


Leu Tyr Glu Ala Lys Thr Gln Gly Arg Asn Arg Val Val Val Phe 
                165                 170                 175 


<210>  6
<211>  130
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  UvrD-like helicase C-terminal domain of the ATP-dependent 
       exoDNAse

<400>  6

Glu Asp Gln Arg Arg Ala Ala Glu Ala Ala Ile Leu Val Glu Arg Val 
1               5                   10                  15      


Gln Ala Met Val Gly Glu Ala Gly Pro Ala Met Ala Val Arg Gly Lys 
            20                  25                  30          


Asp Arg Gln Glu Arg Pro Ala Arg Tyr Ser Asp Ile Leu Ile Leu Thr 
        35                  40                  45              


Arg Arg Thr Thr Gln Leu Ala Val Tyr Glu Ala Ala Leu Arg His Ala 
    50                  55                  60                  


Gly Ile Pro Phe Val Ser Pro Gly Arg Gly Gly Leu Leu Asn Thr Leu 
65                  70                  75                  80  


Glu Ala Gln Asp Leu Leu Ala Thr Leu Arg Phe Leu Ala Asp Pro Gly 
                85                  90                  95      


Asp Asn Leu Ala Leu Ala Gln Val Leu Arg Met Pro Ala Phe Gly Leu 
            100                 105                 110         


Gly Asp Asp Val Leu Leu Ala Leu Ser Ala Gln Pro Gly Gln Ala Trp 
        115                 120                 125             


Trp His 
    130 


<210>  7
<211>  26
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  Peptide fragment

<400>  7

Ala Gly Arg Arg Ser Pro Asp Leu Gln Gly Glu Thr Thr Ala Tyr Pro 
1               5                   10                  15      


Ala Ile Arg Met Gly Asp Leu Arg Gly Leu 
            20                  25      


<210>  8
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<223>  Peptide fragment

<400>  8

Arg Glu Gly Ala Ser Pro Thr Pro Arg Gly Tyr Leu 
1               5                   10          


